<code id='AA935F9EB4'></code><style id='AA935F9EB4'></style>
    • <acronym id='AA935F9EB4'></acronym>
      <center id='AA935F9EB4'><center id='AA935F9EB4'><tfoot id='AA935F9EB4'></tfoot></center><abbr id='AA935F9EB4'><dir id='AA935F9EB4'><tfoot id='AA935F9EB4'></tfoot><noframes id='AA935F9EB4'>

    • <optgroup id='AA935F9EB4'><strike id='AA935F9EB4'><sup id='AA935F9EB4'></sup></strike><code id='AA935F9EB4'></code></optgroup>
        1. <b id='AA935F9EB4'><label id='AA935F9EB4'><select id='AA935F9EB4'><dt id='AA935F9EB4'><span id='AA935F9EB4'></span></dt></select></label></b><u id='AA935F9EB4'></u>
          <i id='AA935F9EB4'><strike id='AA935F9EB4'><tt id='AA935F9EB4'><pre id='AA935F9EB4'></pre></tt></strike></i>

          focus

          focus

          author:explore    Page View:669
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Medicare drug price negotiation continues, as pharma counteroffers
          Medicare drug price negotiation continues, as pharma counteroffers

          PresidentBiden'sWhiteHouseonMondayballyhooedaroutinestepinMedicare’snewprogramtonegotiatethepricesof

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          Lack of health data on LGBTQ+ people has serious consequences

          FrankFranklinII/APLackofhealthdataonLGBTQ+peoplehasreal-worldconsequences.Aparticipantina2020reportf